All In Biotech

Drug Trial Radar · NCT06752668

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

248

Planned (sponsor's estimate)

Start

Dec 23, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Dec 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. * IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton (also known as ORX750) is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.

Conditions

  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Idiopathic Hypersomnia

Interventions

  • ORX750Drug

    ORX750 capsule.

  • PlaceboDrug

    ORX750 matching placebo capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Up to Day 35
  2. Number of Participants With Abnormal Changes From Baseline in Laboratory TestsTime frame: Up to Day 35
  3. Number of Participants With Abnormal Change From Baseline in Vital SignsTime frame: Up to Day 35
  4. Number of Participants With Abnormal Change From Baseline in Electrocardiograms (ECG)Time frame: Up to Day 35
  5. Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 35

Locations

37 sites in 5 countries. Site status is shown where the registry gives one.

  • Auburn, Alabama

    Auburn, Alabama · Recruiting

  • Chandler, Arizona

    Chandler, Arizona · Recruiting

  • Scottsdale, Arizona

    Scottsdale, Arizona · Recruiting

  • Long Beach, California

    Long Beach, California · Recruiting

  • Santa Ana, California

    Santa Ana, California · Recruiting

  • Brandon, Florida

    Brandon, Florida · Recruiting

  • Miami, Florida

    Miami, Florida · Recruiting

  • Miami, Florida

    Miami, Florida · Recruiting

  • Orlando, FL

    Orlando, Florida · Recruiting

  • Winter Park, Florida

    Winter Park, Florida · Recruiting

  • Atlanta, Georgia

    Atlanta, Georgia · Recruiting

  • Atlanta, Georgia

    Atlanta, Georgia · Recruiting

  • Riverdale, Georgia

    Riverdale, Georgia · Recruiting

  • New Orleans, Louisiana

    New Orleans, Louisiana · Recruiting

  • Newton, Massachusetts

    Newton, Massachusetts · Recruiting

  • Southfield, Michigan

    Southfield, Michigan · Recruiting

  • Sterling Heights, Michigan

    Sterling Heights, Michigan · Recruiting

  • Henderson, Nevada

    Henderson, Nevada · Recruiting

  • Denver, North Carolina

    Denver, North Carolina · Recruiting

  • Huntersville, North Carolina

    Huntersville, North Carolina · Recruiting

  • Cincinnati, Ohio

    Cincinnati, Ohio · Recruiting

  • Cleveland, OH

    Cleveland, Ohio · Recruiting

  • Dublin, Ohio

    Dublin, Ohio · Recruiting

  • Willow Grove, Pennsylvania

    Willow Grove, Pennsylvania · Recruiting

  • Columbia, South Carolina

    Columbia, South Carolina · Recruiting

  • North Charleston, South Carolina

    North Charleston, South Carolina · Recruiting

  • Austin, Texas

    Austin, Texas · Recruiting

  • El Paso, TX

    El Paso, Texas · Recruiting

  • San Antonio, Texas

    San Antonio, Texas · Recruiting

  • Toronto, Ontario

    Toronto, Ontario, Canada · Recruiting

  • Leon, France

    Léon, Bordeaux, France · Recruiting

  • Bologna, Italy

    Bologna, Italy · Recruiting

  • Pozzilli, Italy

    Pozzilli, Italy · Recruiting

  • Verona, Italy

    Verona, Italy · Recruiting

  • Madrid, Spain

    Madrid, Spain · Recruiting

  • Madrid, Spain

    Madrid, Spain · Recruiting

  • Vitoria-Gasteiz, Spain

    Vitoria-Gasteiz, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.